Becton Dickinson and Co Depositary ETF News

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.38% and 8.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Becton, Dickinson (NYSE:BDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 24.55% year over year to $2.74, which beat the estimate o

BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.

David Katz, Matrix Asset Advisors chief investment officer, and Jerry Castellini, CastleArk Management chief investment officer, join 'The Exchange' to discuss their market outlook as the economy reop

Becton Dickinson and Co (NYSE: BDX) will build a €165 million ($200 million) high-tech manufacturing facility in Zaragoza, Spain, that will create up to 600 jobs by 2030. BD plans to begin constr

, a leading global medical technology company, announced that its Board of Directors have unanimously authorized management to go ahead with a plan to spinoff the Diabetes Care business into an indepe

Becton, Dickinson & Co. ( BDX , Financial) delivered another strong top and bottom-line beat when it reported earnings results last week.

CNBC's "Power Lunch" team discusses syringe supply and the Covid supply chain with Becton, Dickinson CEO Tom Polen.

Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.

While reporting financial results for the second fiscal quarter of the year, during which revenues grew more than 15% to $4.9 billion, Becton Dickinson and Co (NYSE: BDX) also laid out its plans

Becton Dickinson (BDX) delivered earnings and revenue surprises of 4.93% and 1.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson & Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by $480 million in COVID-19 testing sales, and announced plans to separate its Dia

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Becton, Dickinson is a market leader in multiple medical supply, laboratory, and diagnostic product categories. The company has deleveraged after two major acquisitions and the leverage ratio is now n